Eperisone is an effective central muscle relaxant for the treatment of musculoskeletal pain

Churyukanov M.V.; Kukushkin M.L.

doi:https://doi.org/10.17116/pain20242201147

Close metadata

Recommended articles:

The Keele stratification tool for targeted treatment of musculoskeletal pain (Keele STarT MSK Tool): linguistic adaptation of the Russian-language version. Russian Journal of Pain. 2024;(4):30-34

L-lysine aescinate for back pain: a systematic review. Russian Journal of Pain. 2024;(4):46-54

Muscle relaxant selection criteria for musculoskeletal pain. Russian Journal of Pain. 2024;(4):55-64

Recurrent pain syndromes in adolescents of different ages. Russian Journal of Pain. 2025;(2):24-31

Biofeedback in complex therapy of pain syndromes. Russian Journal of Pain. 2025;(2):70-75

Obesity and musculoskeletal pain: possibilities of pharmacotherapy. A narrative overview. Russian Journal of Pain. 2025;(3):73-81

Sanogenetic mechanisms of cyclic local traction therapy in the treatment of neurological manifestations of degenerative diseases in the spine. (Literature review). Problems of Balneology, Physiotherapy and Exercise Therapy. 2024;(5):74-83

The effectiveness of using a centrally acting muscle relaxant in combination with botulinum toxin injections in patients with spasmodic torticollis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(9):99-102

Abstract:

Diseases of the musculoskeletal system, musculoskeletal pain, primarily nonspecific back pain (NSBP), are one of the most significant medical and social problems in the world. This is due to the widespread prevalence of this pathology, the level of suffering of patients, a high proportion of violations of labor function and a decrease in quality of life due to chronic pain in the lower back (LBP). To treat diseases of the musculoskeletal system (including NSBP), various non-drug and pharmacotherapeutic methods are used. The most effective and frequently prescribed are nonsteroidal anti-inflammatory drugs and centrally acting muscle relaxants. The latter includes a new drug in Russia, eperisone (Stezium, extended-release tablets, 75 mg*). Eperisone has a multifactorial effect, its main pharmacological effects are relaxation of skeletal muscles, analgesic, vascular antispasmodic effect (with an increase in blood flow in the muscles) and suppression of neurogenic inflammation. Numerous clinical studies have shown the high effectiveness of the drug for LBP and a number of other types of musculoskeletal pain. In terms of the severity of this property, eperisone is comparable to other drugs in this group, and in some cases surpasses them. A distinctive feature of eperisone (Stezium) is a relatively high safety and tolerability profile, with infrequent and mild adverse events (including weak sedative effects), which is regarded as a positive property.

Keywords:

musculoskeletal pain

back pain

muscle relaxants

eperisone

Stezium

Authors:

Churyukanov M.V.

Sechenov First Moscow State Medical University (Sechenov University);
Petrovsky Russian Scientific Center of Surgery

ORCID: 0000-0001-6542-1963

Kukushkin M.L.

Research Institute of General Pathology and Pathophysiology

ORCID: 0000-0002-9406-5846

Received:

10.01.2024

Accepted:

19.01.2024

Close metadata

References:

Van Filden M, Koes B. Low Back Pain. Wall and Melzack’s Textbook of pain, Sixth edition, Elsevier, 2013.
GBD 2021 Low Back Pain Collaborators. Global, regional, and national burden of low back pain, 1990-2020, its attributable risk factors, and projections to 2050: A systematic analysis of the Global Burden of Disease Study 2021. Lancet Rheumatol. 2023;5(6):e316-e329. https://doi.org/10.1016/S2665-9913(23)00098-X
Nasonov EL, Yakhno NN, Karateev AE, et al. General principles of treatment for musculoskeletal pain: Interdisciplinary consensus. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(3):247-265. (In Russ.).
Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D. Survey of chronic pain in Europe: Prevalence, impact on daily life, and treatment. Eur J Pain. 2006;10:287-333. https://doi.org/10.1016/j.ejpain.2005.06.009
Safiri S, Kolahi AA, Cross M, et al. Prevalence, deaths, and disability-adjusted life years due to musculoskeletal disorders for 195 countries and territories 1990—2017. Arthritis Rheumatol. 2021;73:702-714. https://doi.org/10.1002/art.41571
Cieza A, Causey K, Kamenov K, Hanson SW, Chatterji S, Vos T. Global estimates of the need for rehabilitation based on the Global Burden of Disease study 2019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2021;396(10267):2006-2017. https://doi.org/10.1016/S0140-6736(20)32340-0
World Health Organization. Musculoskeletal health. 14 July 2022. https://www.who.int/news-room/fact-sheets/detail/musculoskeletal-conditions
Data from Institute for Health Metrics and Evaluation (IHME) VizHub and WHO Rehabilitation Needs Estimator.
Yahno NN, Kukushkin ML, Churyukanov MV, Syrovegin AV. The results of open multicentral study «Meridian» for assessment of pain syndromes prevalence in ambulatory and therapeutic preferences of physicians. Russian Journal of Pain. 2012;3(36-37):10-14. (In Russ.).
Van Tulder MW, Touray T, Furlan AD, Solway S, Bouter LM. Muscle relaxants for non-specific low back pain (Review). Cochrane Database of Systematic Reviews. 2003;4:CD004252. https://doi.org/10.1002/14651858.CD004252
Chou R, Peterson K, Helfand M. Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: A systematic review. J Pain Symptom Manage. 2004;28(2):140-175. https://doi.org/10.1016/j.jpainsymman.2004.05.002
Shaheed AC, Maher CG, Williams KA, McLachlan AJ. Efficacy and tolerability of muscle relaxants for low back pain: Systematic review and metaanalysis. Eur J Pain. 2017;21(2):228-237. https://doi.org/10.1002/ejp.907
Chang WJ. Muscle Relaxants for Acute and Chronic Pain. Phys Med Rehabil Clin N Am. 2020;31(2):245-254. https://doi.org/10.1016/j.pmr.2020.01.005
Cashin AG, Folly T, Bagg MK, Wewege MA, Jones MD, Ferraro MC, Leake HB, Rizzo RRN, Schabrun SM, Gustin SM, Day R, Williams CM, McAuley JH. Efficacy, acceptability, and safety of muscle relaxants for adults with non-specific low back pain: systematic review and meta-analysis. BMJ. 2021;374:n1446. PMID: 34233900; PMCID: PMC8262447. https://doi.org/10.1136/bmj.n1446
Gianola S, Bargeri S, Del Castillo G, Corbetta D, Turolla A, Andreano A, Moja L, Castellini G. Effectiveness of treatments for acute and subacute mechanical non-specific low back pain: A systematic review with network meta-analysis. Br J Sports Med. 2022;56(1):41-50. https://doi.org/10.1136/bjsports-2020-103596
Melilli B, Piazza C, Vitale DC, Marano MR, Pecori A, Mattana P, Volsi VL, Iuculano C, Cardì F, Drago F. Human pharmacokinetics of the muscle relaxant, eperisone hydrochloride by liquid chromatography-electrospray tandem mass spectrometry. Eur J Drug Metab Pharmacokinet. 2011;36(2):71-78. Epub 2011 Mar 30. PMID: 21448778. https://doi.org/10.1007/s13318-011-0034-0
Baek IH, Back HM, Chae JW, Ha ES, Park H, Choi DH, Staatz CE, Kim MS. Pharmacokinetics of eperisone following oral administration in healthy Korean volunteers. Biopharm Drug Dispos. 2021;42(2-3):94-102. https://doi.org/10.1002/bdd.2264
Inoue S, Bian K, Okamura T, Okunishi H, Toda N. Mechanisms of action of eperisone on isolated dog saphenous arteries and veins. Jpn J Pharmacol. 1989;50(3):271-282. PMID: 2761129. https://doi.org/10.1254/jjp.50.271
Iwase S, Mano T, Saito M, Ishida G. Effect of a centrally-acting muscle relaxant, eperisone hydrochloride, on muscle sympathetic nerve activity in humans. Funct Neurol. 1992;7(6):459-470.
A phase I clinical trial to compare the pharmacokinetics and safety of eperisone HCl SR 75 mg and Myonal tablet 50 mg after oral administration in healthy adult male subjects. 2013.
A randomized, open-label, single-dose, crossover clinical trial to evaluate the food effect on the pharmacokinetics of eperisone HCl SR tablet 75 mg after oral administration in healthy adult male subjects (Phase I). 2013.
Instructions for medical use of the medicinal product (General characteristics of the medicinal product) Eperisone (Stezium), 75 mg, extended-release, film-coated tablets. (In Russ).
Pinzon RT, Sanyasi RDe LR. Systematic Review of Eperisone for Low Back Pain. Asian Journal of Pharmacy and Pharmacology. 2018;4(2):140-146. https://doi.org/10.31024/ajpp.2018.4.2.7
Sakai Y, Matsuyama Y, Nakamura H, Katayama Y, Imagama S, Ito Z, Okamoto A, Ishiguro N. The effect of muscle relaxant on the paraspinal muscle blood flow: A randomized controlled trial in patients with chronic low back pain. Spine (Phila Pa 1976). 2008;33(6):581-587. PMID: 18344850. https://doi.org/10.1097/BRS.0b013e318166e051
Bresolin N, Zucca C, Pecori A. Efficacy and tolerability of eperisone and baclofen in spastic palsy: A double-blind randomized trial. Adv Ther. 2009;26:563-573. https://doi.org/10.1007/s12325-009-0031-8
Park KH, Lee SC, Yuk JE, Kim S-R, Lee J-H, Park J-W. Eperisone-Induced Anaphylaxis: Pharmacovigilance Data and Results of Allergy Testing. Allergy Asthma Immunol Res. 2019;11(2):231-240. https://doi.org/10.4168/aair.2019.11.2.231
Cochrane Library. https://www.cochranelibrary.com/search
https://pubmed.ncbi.nlm.nih.gov/?term=eperisone
Myonal Basic prescribing info. https://www.mims.com/philippines/drug/info/myonal?type=full
Kalofonos I, Stahly GP, Martin-Doyle W, et al. Novel form of eperisone. Patent Application Publication. Pub. No. US 2011/0281911A1. Pub. Date: Nov 17, 2011. https://patentimages.storage.googleapis.com/6c/7a/4a/31483b7d6a8e2b/US20110281911A1.pdf
Bresolin N, Zucca C, Pecori A. Efficacy and tolerability of eperisone in patients with spastic palsy: A cross-over, placebo-controlled dose-ranging trial. Eur Rev Med Pharmacol Sci. 2009;13(5):365-370.
Bose K. The efficacy and safety of eperisone in patients with cervical spondylosis: results of a randomized, double-blind, placebo-controlled trial. Clinical Trial Methods Find Exp Clin Pharmacol. 1999;21(3):209-213. https://doi.org/10.1358/mf.1999.21.3.534831
Asaro C, Scaturro D, Tomasello S, Tumminelli LG, Letizia Mauro G. Synergistic Effect of Physical Therapy Plus Pharmacological Therapy with Eperisone in Tension-Type Cervicalgia. Muscles, Ligaments and Tendons Journal. 2019;9(4):635-641.
Bavage S, Durg S, Ali Kareem S, Dhadde SB. Clinical efficacy and safety of eperisone for low back pain: A systematic literature review. Pharmacol Rep. 2016;68(5):903-912. https://doi.org/10.1016/j.pharep.2016.05.003
Chandanwale AS, Chopra A, Goregaonkar A, Medhi B, Shah V, Gaikwad S, Langade DG, Maroli S, Mehta SC, Naikwadi A, Pawar DR. Evaluation of eperisone hydrochloride in the treatment of acute musculoskeletal spasm associated with low back pain: A randomized, double-blind, placebo-controlled trial. J Postgrad Med. 2011;57(4):278-285. PMID: 22120855. https://doi.org/10.4103/0022-3859.90076
Sartini S, Guerra L. Open experience with a new myorelaxant agent for low back pain. Adv Ther. 2008;25(10):1010-1018. https://doi.org/10.1007/s12325-008-0108-9
Beltrame A, Grangiè S, Guerra L. Clinical experience with eperisone in the treatment of acute low back pain. Minerva Med. 2008;99(4):347-352.
Cabitza P, Randelli P. Efficacy and safety of eperisone in patients with low back pain: A double blind randomized study. Eur Rev Med Pharmacol Sci. 2008;12(4):229-235.
Rossi M, Ianigro G, Liberatoscioli G, Di Castelnuovo A, Grimani V, Garofano A, Camposarcone N, Nardi LF. Eperisone versus tizanidine for treatment of chronic low back pain. Minerva Med. 2012;103(3):143-149. PMID: 22653094.
Khan AF, Parveen K, Khan AS. Efficacy and tolerability of eperisone versus tizanidine in patients suffering from low back pain with muscle spasm. Int J Res Med Sci. 2017;5(6):2694-2700. https://doi.org/10.18203/2320-6012.ijrms20172472
Pinzon RT, Wijaya VO, Paramitha D, Bagaskara RR. Effects of eperisone hydrochloride and non-steroid anti-inflammatory drugs (NSAIDs) for acute non-specific back pain with muscle spasm: A prospective, open-label study. Drug Healthc Patient Saf. 2020;12:221-228. https://doi.org/10.2147/DHPS.S278467
Rusinyol FC, Pericé RV, Boronat ER, Bosch FF. Effects of two different doses of eperisone in the treatment of acute low back pain. The Journal of Applied Research. 2009;9:23-29.
Rani S, Kumar S, Joyti, Vaerma PK, Lamba D, Saini R. To compare the efficacy and safety of eperisone with thiocolchicoside in patients with acute lower backache associated with muscle spasm. Indian J Pharm Pharmacol. 2016;3(2):79-83.
Maaz SH, Khandelwal PN, Baig SM, Doifode SM, Ghotkar UM. Evaluation of efficacy and tolerability of eperisone and thiocolchicoside in treatment of low back pain associated with muscle spasm: An open label, prospective, randomized controlled trial. International Journal of Basic and Clinical Pharmacology. 2016;5(6):2669-2674. https://doi.org/10.18203/2319-2003.ijbcp20164144
A multicenter, randomized, double-blinded, parallel, activecontrolled, phase III clinical trial to evaluate the efficacy and safety of DW-1030 and Eperisone HCl in acute back pain patients. 2014.
Kim MJ, Lim H-S, Noh Y-H, Kim YH, Choi HY, Park K-M, Kim S-E, Bae K-S. Pharmacokinetic interactions between eperisone hydrochloride and aceclofenac: A randomized, open-label, crossover study of healthy Korean men. Clin Ther. 2013;35(10):1528-35. Epub 2013 Sept 16. PMID: 24050970. https://doi.org/10.1016/j.clinthera.2013.08.012
Eisai Co. myonal drug information. 2012. Accessed June 24, 2013. https://www.eisai.jp/medical/products/di/EPI/MYO_T-G_EPI.pdf
Ryu J-H, Kim J-I, Kim HS, Noh G-J, Lee K-T, Chung EK. Pharmacokinetic interactions between pelubiprofen and eperisone hydrochloride: A randomized, open-label, crossover study of healthy Korean men. Clin Ther. 2017;39(1):138-149.